Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis. [electronic resource]
Producer: 20040304Description: 595-601 p. digitalISSN:- 0105-4538
- Administration, Inhalation
- Adult
- Allergens -- adverse effects
- Anti-Allergic Agents -- therapeutic use
- Betula -- adverse effects
- Biomarkers -- blood
- Chemokines, CC -- blood
- Conjunctivitis, Allergic -- blood
- Desensitization, Immunologic
- Drug Therapy, Combination
- Edible Grain -- adverse effects
- Female
- Histamine H1 Antagonists, Non-Sedating -- therapeutic use
- Humans
- Hypersensitivity, Immediate -- blood
- Immunoglobulin E -- blood
- Loratadine -- therapeutic use
- Male
- Poaceae -- adverse effects
- Poland -- epidemiology
- Pollen -- adverse effects
- Rhinitis, Allergic, Seasonal -- blood
- Statistics as Topic
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Evaluation Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.